Managing Pharmaceutical Operations – Current Good Manufacturing Practices Risk

Description

This whitepaper provides detailed analysis of FDA enforcement actions and regulatory trends in pharmaceutical manufacturing operations from 2023-2025. It examines cGMP subparts with disproportionately high operational risk including Subpart F (Production and Process Controls at 18% of citations), Subpart I (Laboratory Controls at 25% of citations), and Subpart J (Records and Reports at 18% of citations). The document identifies data integrity as the primary compliance challenge (over 30% of FDA citations), Quality Unit oversight failures, and emerging regulatory initiatives including the Advanced Manufacturing Technologies Designation Program, Continuous Manufacturing Guidance (ICH Q13), and FDA PreCheck for domestic manufacturing. It also covers digital transformation with Pharma 4.0, AI/ML applications, and comprehensive strategies for mitigating operations risk.